



## Mithra Signs License and Supply Agreement for Commercialization of Myring™ in Venezuela

- Mithra grants license to Chemical Dampe for commercialization of its vaginal contraceptive ring in Venezuela
- Strengthening of the commercial presence in Latin and South America
- Myring™ licenses granted to industry leaders in 36 countries, including the world's three largest markets

**Liege, Belgium, 10 November 2020 – 7:30 CET** – Mithra (Euronext Brussels: MITRA), a company dedicated to Women's Health, today announces that it has entered into a license and supply agreement (LSA) with Chemical Dampe for the commercialization of its hormonal contraceptive ring Myring™ in Venezuela. Based in Venezuela, Chemical Dampe builds alliances for the health of Venezuelans focused on women's health with advanced technology and high quality products, made inside and outside its borders.

Under the terms of this agreement, Chemical Dampe will distribute Myring™ in Venezuela. Mithra will receive an upfront payment and will be eligible to receive milestone payments and recurring revenues based on minimum annual quantities (MAQ). Moreover, Mithra will manufacture Myring™ at its Contract Development and Manufacturing Organization facility in Belgium.

To date, Mithra has licensed Myring™ to industry leaders in 36 countries, including the three biggest worldwide markets (United States, Germany and Italy) and 6 regions in Latin and South America (Venezuela, Argentina, Chili, Mexico, the Dominican Republic and Paraguay).

**François Fornieri, CEO Mithra Women's Health, commented:** *"We are very pleased to count Chemical Dampe amongst our global partners. The opportunity to grow the Venezuelan market is great, considering the economic and political turmoil of the past, which had temporarily forced transnational pharmaceutical companies to stop in-country operations. Gynecologists, through the Venezuelan Society of Gynecology, have requested the presence of new brands with advanced technology in the country to serve Venezuelan patients. In parallel to the commercialization of our hormonal contraceptive ring in Europe, and despite the occurrence of the global health pandemic, we continue to pursue the international expansion strategy."*

\*\*\*\*\*

### For more information, please contact:

**Alexandra Deschner (IRO)** : +32 490 58 35 23 - [investorrelations@mithra.com](mailto:investorrelations@mithra.com)

**Carole Kousis (Press)** : +32 4 349 28 22 – [press@mithra.com](mailto:press@mithra.com)

### About Mithra

Mithra (Euronext: MITRA) is a Belgian biotech company dedicated to transforming Women's Health by offering new choices through innovation, with a particular focus on contraception and menopause. Mithra's goal is to develop products offering better efficacy, safety and convenience, meeting women's needs throughout their life span. Its three lead development candidates are built on Mithra's unique native estrogen platform, Estetrol (E4): Estelle®, a new era in oral contraception, PeriNesta®, the first complete oral treatment for perimenopause and Donesta®, the next-generation hormone therapy. Mithra also develops and manufactures complex therapeutics in the areas of contraception, menopause and hormone-dependent cancers. It offers partners a complete spectrum of research, development and specialist manufacturing at its technological platform Mithra CDMO. Active in more than 100 countries around the world, Mithra has an approximate headcount of 250 staff members and is headquartered in Liège, Belgium. [www.mithra.com](http://www.mithra.com)

### About Myring™

Myring™ (etonogestrel/ethinyl estradiol vaginal ring) is a non-biodegradable, flexible, transparent, combination contraceptive vaginal ring, with an outer diameter of 54 mm and a cross-sectional diameter of 4 mm. It is made of ethylene vinylacetate copolymers, and contains 11.7 mg etonogestrel and 2.7 mg ethinyl estradiol. When placed in the vagina, each ring releases, in line with the originator (Nuvaring®), on average 0.120 mg/day of etonogestrel and 0.015 mg/day of ethinyl estradiol over a three-week period of use. The ring is to remain in place continuously for three weeks. It is removed for a one-week break, during which a withdrawal bleed usually occurs. A new ring is inserted one week after the last ring was removed.

### Important information

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates", "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.



News  
Alerts

Subscribe to our mailing list on [investors.mithra.com](http://investors.mithra.com) to receive our press releases by email or follow us on our social media :

[Linkedin](#) • [Twitter](#) • [Facebook](#)